Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Catheter Cardiovasc Interv. 2020 Jul;96(1):112-113. doi: 10.1002/ccd.29082.
Ticagrelor monotherapy after a short course of aspirin is emerging as the predominant aspirin-free strategy among patients undergoing percutaneous coronary intervention. In patients included in the GLOBAL-LEADERS trial, the treatment effect of the experimental (dual antiplatelet therapy with aspirin and ticagrelor for 1 month followed by ticagrelor monotherapy) versus control strategy remained consistent irrespective of the presence or absence of coronary bifurcation. Ticagrelor monotherapy represents a safe and effective antiplatelet strategy for the treatment of patients who undergo percutaneous coronary intervention of bifurcation lesions.
替格瑞洛单药治疗在短期阿司匹林治疗后成为经皮冠状动脉介入治疗患者中主要的无阿司匹林治疗策略。在 GLOBAL-LEADERS 试验中纳入的患者中，无论是否存在冠状动脉分叉，实验组（阿司匹林双联抗血小板治疗 1 个月后替格瑞洛单药治疗）与对照组策略的治疗效果保持一致。替格瑞洛单药治疗代表了一种安全有效的抗血小板策略，适用于接受冠状动脉分叉病变经皮冠状动脉介入治疗的患者。
